AIIMS Brain Stent Trial has marked a historic moment in India’s healthcare journey, especially in the field of stroke treatment. For the first time, a fully indigenous and dedicated clinical trial for an advanced brain stent has been successfully conducted within the country. Led by AIIMS Delhi, this achievement not only strengthens India’s stroke care ecosystem but also places the nation among a small group of countries capable of producing world-class clinical evidence for complex neurointerventional devices.

Thank you for reading this post, don't forget to subscribe!

A Landmark Moment for Stroke Treatment in India

Stroke is one of the leading causes of death and long-term disability in India. Large vessel occlusion strokes, which block major arteries supplying the brain, are especially dangerous and require quick and highly skilled intervention. Until now, most advanced stroke devices used in India were tested and validated abroad. The AIIMS Brain Stent Trial has changed this reality.

The clinical trial, named GRASSROOT, evaluated the Supernova brain stent developed by Gravity Medical Technology. It was designed to test how safe and effective the device is in treating severe strokes. AIIMS Delhi played a central role as the national coordinating centre and also served as the lead site for patient enrolment. The trial was conducted across eight major medical centres in India, ensuring a diverse and representative patient population.

What Makes the GRASSROOT Trial Special

The GRASSROOT trial is significant because it is the first time a novel stroke device has been clinically tested, validated, and approved in India using only domestic data. This means Indian doctors, researchers, and regulators worked together at every stage, from trial design to final approval.

Patients enrolled in the AIIMS Brain Stent Trial were suffering from life-threatening large vessel occlusion strokes. These cases demand rapid restoration of blood flow to the brain to prevent permanent damage or death. The Supernova stent was used during minimally invasive procedures to remove blood clots and reopen blocked vessels. The trial carefully monitored patient outcomes, safety indicators, and recovery patterns.

Strong Clinical Results and National Approval

The results of the AIIMS Brain Stent Trial were highly encouraging. The Supernova stent demonstrated excellent safety and strong effectiveness in restoring blood flow during severe strokes. Complication rates were low, and many patients showed meaningful neurological improvement after treatment.

These findings were published in the Journal of Neurointerventional Surgery, a respected international journal that is part of the British Medical Journal group. Publication in such a journal highlights the scientific quality and global relevance of the trial.

Based on the positive outcomes, the Central Drugs Standard Control Organisation approved the Supernova stent-retriever for routine clinical use in India. This approval is historic because it makes Supernova the country’s first stroke device to be cleared entirely on the basis of an Indian clinical trial.

Innovation Designed for Indian Needs

One of the most important aspects of the AIIMS Brain Stent Trial is that the Supernova stent has been designed with Indian patients in mind. In India, strokes often occur at a younger age compared to many Western countries. Factors such as lifestyle changes, high rates of diabetes and hypertension, and limited early screening contribute to this trend.

The Supernova stent was developed under the Make-in-India initiative, aiming to create advanced medical technology that is both effective and accessible. Before its formal approval in India, the device had already been used to treat over 300 patients across Southeast Asia, adding to confidence in its real-world performance.

With plans for domestic manufacturing, the stent is expected to become more affordable than imported alternatives. Lower costs can make advanced stroke care available to a larger number of hospitals and patients, especially in regions where resources are limited.

Role of AIIMS Delhi in Advancing Medical Research

AIIMS Delhi has long been a leader in medical education, patient care, and research. Through the AIIMS Brain Stent Trial, the institution has shown that Indian centres can successfully manage complex, multi-centre clinical trials that meet global standards.

By acting as the national coordinating centre, AIIMS ensured uniform protocols, high ethical standards, and accurate data collection across all participating hospitals. This experience will help India conduct more advanced trials in the future, not only in neurology but also in other specialised fields.

Impact on India’s Healthcare and Innovation Ecosystem

Experts believe that the success of the AIIMS Brain Stent Trial represents a turning point for Indian medical innovation. It proves that India does not have to rely solely on foreign data for approving advanced medical devices. Instead, the country can generate its own high-quality evidence that reflects local patient needs and conditions.

This achievement is expected to boost confidence among Indian researchers, startups, and investors working in medical technology. It may also encourage faster development and approval of life-saving devices, reducing delays in patient access to new treatments.

For patients, the long-term impact could be significant. With more affordable and locally validated stroke devices, hospitals across India may be better equipped to handle the growing burden of stroke, which affects an estimated 1.7 million people in the country every year.

A New Chapter in Stroke Care

The AIIMS Brain Stent Trial stands as a symbol of what Indian healthcare can achieve through collaboration, innovation, and commitment to patient needs. By successfully testing and approving an indigenous brain stent, India has taken a confident step toward self-reliance in advanced medical care and research.

As more such initiatives emerge, the country’s ability to provide timely, effective, and affordable treatment for critical conditions like stroke is set to improve, offering hope to millions of patients and families across the nation.